GLP-1 receptor agonists × glycemic control

TrialBMJ (Clinical research ed.)2015

Liraglutide in people treated for type 2 diabetes with multiple daily insulin injections: randomised clinical trial (MDI Liraglutide trial).

Marcus Lind et al.PubMed ↗Full text ↗Publisher ↗

What the trial testedrandomised · 124 people · 2015

Randomised comparison

Probably lowered glycemic control

−12.3mmol/mol−15.8 to −8.80

As reported

difference −12.3 mmol/mol, 95% CI −15.8 to −8.80

One number in the abstract

the abstract, start to end

mmol/mol (0.4%) for placebo, difference -12.3 mmol/mol (95% confidence

← favours treatmentfavours comparator →
could be chance
Glycemic control
−12.3−15.8 to −8.80
GLP-1 receptor agonistsGlycemic control

GLP-1 receptor agonists × glycemic controlhelps?replicated

unlikelylikely
0.910.92 without it
← favours comparatorfavours treatment →
this papermore certainless certain
1 / 5

34 papers cite it

2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
this paperpooled ittrialcites it

The trial

Full record →Abstract, authors, funding and every citing paper · PMID 26512041